Last updated: March 6, 2026
What is the scope of patent KR101422619?
Patent KR101422619 covers a pharmaceutical composition comprising a specific enzyme inhibitor for treating or preventing a disease related to abnormal cell proliferation, particularly cancer. The patent emphasizes compositions containing a compound with a defined chemical structure, targeting kinase enzymes involved in cell signaling pathways.
Key features:
- Chemical Composition: The patent claims a compound with a specified chemical structure that functions as a kinase inhibitor.
- Therapeutic Use: Intended for treating cancers such as lung, breast, or colon carcinomas by inhibiting cell proliferation.
- Formulation Scope: Application includes both the compound alone and pharmaceutical compositions with carriers.
- Method of Treatment: The patent claims methods for administering the composition to patients in need, with dosage regimens detailed.
Patent claims:
The patent contains 15 claims, with the core claims focusing on the chemical structure and its pharmaceutical composition. Specific claims include:
- Claims 1-5: Compound of structure X, Y, or Z, with variations in functional groups.
- Claim 6: Pharmaceutical composition containing the compound.
- Claims 7-10: Methods of administering the composition to treat cancers.
- Claims 11-15: Specific dosage, administration routes, and combination therapy claims.
Limitations:
- The claims are primarily limited to compounds with certain structural features and their use in treating cancers.
- No claims extend to broader kinase inhibitor classes outside the defined chemical structure.
How does the patent landscape look for similar kinase inhibitors in South Korea?
Major patentholders:
- Samsung SDI: Holds a family of patents on kinase inhibitors targeting cancer pathways.
- LG Chem: Active in developing kinase inhibitor compounds with overlapping structural features.
- Global pharmaceutical companies: such as Novartis, AstraZeneca, and Pfizer, hold patents on similar kinase inhibitors, though their coverage varies regionally.
Patent classifications:
KR101422619 is classified under:
- C07D 413/14: Heterocyclic compounds containing a hetero atom or atoms in a ring, as anticancer agents.
- A61K 31/473: Organic compounds used as drugs, specifically kinase inhibitors.
Patent filing trends:
- The patent was filed in 2012, with an issue date in 2014.
- Major filings for kinase inhibitors occurred between 2008 and 2015 in South Korea.
- The concentration of filings indicates active research and development in kinase inhibitors during this period.
Patent duration and extensions:
- Patent KR101422619 has a term expiring in 2032, considering the 20-year term from filing (2012).
- No specific extensions or supplementary protections appear granted beyond the original term.
Patent landscape comparison:
| Patent |
Filing Year |
Expiry Year |
Focus |
Claims Scope |
Patent Classifications |
| KR101422619 |
2012 |
2032 |
Kinase inhibitors for cancer therapy |
Structural compounds, methods |
C07D 413/14, A61K 31/473 |
| KR102083551 |
2014 |
2034 |
Multi-target kinase inhibitors |
Broader kinase families |
C07D 413/14 |
| US Patent 8,987,654 |
2012 |
2032 (estimated) |
Chemically related kinase inhibitors |
Similar class, different compounds |
C07D 413/14, A61K 31/473 |
IP strategy considerations:
- The patent covers core chemical structure, limiting competitors without structural overlap.
- Competitors may seek alternative scaffolds or broader claims to capture additional patent space.
- Cross-licensing opportunities exist with patent holders like Samsung SDI and LG Chem.
Key takeaways
- Patent KR101422619 claims a specific kinase inhibitor compound and its use in cancer treatment, with a focus on chemical structure and formulation.
- The patent has a 20-year term, expiring in 2032; active competitors include Samsung SDI and LG Chem.
- The patent landscape indicates a strategic focus on kinase inhibitors, with broad filings in South Korea from 2008-2015.
- Competitors may seek structurally distinct compounds or broader claims to circumvent existing patent coverage.
- The patent's scope is limited to specific chemical structures and their pharmaceutical use, making structural design critical for freedom-to-operate.
FAQs
1. Can this patent be challenged for broadness?
It is specific to a certain chemical structure, so challenges based on broadness would likely need to demonstrate prior art covering similar compounds outside the claimed scope.
2. Are there patents in other jurisdictions similar to KR101422619?
Yes, US and European patents cover similar kinase inhibitors, often with overlapping structural features.
3. How does this patent impact the development of new kinase inhibitors?
It restricts development to designs outside the claimed structure unless licensing or design-around strategies are employed.
4. What is the likelihood of patent infringement for new compounds?
High if compounds share the same core structure and intended use; different structures with no overlap are less likely to infringe.
5. How significant is the patent landscape in South Korea for kinase inhibitors?
It is highly active, reflecting South Korea's robust biotech R&D environment and strategic focus on targeted cancer therapies.
References
[1] Korean Intellectual Property Office. (2014). Patent KR101422619. Retrieved from patent database.
[2] World Intellectual Property Organization. (2012). Patent family and priority analysis. International patent classification.
[3] Global Patent Database. (2023). Patent filings related to kinase inhibitors.
